Perioperative enfortumab vedotin + pembrolizumab tied to improved outcomes with bladder cancer
Perioperative enfortumab vedotin plus pembrolizumab and surgery lead to significantly better outcomes among patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy compared with surgery ...
Feb 27, 2026
0
7









